The ARHGEF12 Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population with targeted disruption of ARHGEF12 in the HT29 human colorectal adenocarcinoma cell line. This heterogeneous pool of gene-edited cells provides a robust loss-of-function model for studying ARHGEF12-dependent signaling without the clonal selection biases of single-cell-derived knockout lines, making it suitable for pooled functional genomics screens and bulk biochemical analyses.
The HT29 host line was established from a primary colorectal adenocarcinoma of a 44-year-old Caucasian female and serves as a model for intestinal epithelial biology and colorectal cancer research. These adherent cells retain the capacity for enterocytic differentiation, reflecting aspects of intestinal mucosal physiology. HT29 cells display oncogenic mutations in APC and CTNNB1, leading to constitutive Wnt pathway activation, and exhibit altered mucin profiles, making them a relevant platform for investigating colorectal tumorigenesis.
ARHGEF12 encodes LARG, a RhoGEF that activates RhoA, RhoB, and RhoC. LARG couples G protein-coupled receptor signals??elicited by lysophosphatidic acid, thrombin, or sphingosine-1-phosphate??to RhoA activation via direct interaction with G??12/13 subunits. Active RhoA stimulates ROCK1/2 and mDia, leading to myosin light chain (MLC) phosphorylation and actin stress fiber assembly. LARG also interacts with adhesion proteins FAK, p120 catenin, and Plexin-B1, thereby integrating mechanical and adhesive inputs. RhoA signaling drives transcriptional programs through SRF, YAP, and TAZ, regulating genes that control cell proliferation and migration.
Disruption of ARHGEF12 in HT29 cells is anticipated to impair RhoA-dependent cytoskeletal remodeling, leading to defects in cell adhesion, migration, and invasion??processes critical for colorectal cancer metastasis. This knockout model enables dissection of the GPCR?CRhoA?Cactin axis in a colorectal cancer context, particularly how LARG-mediated RhoA activation contributes to the malignant phenotype in response to chemotactic signals or mechanical stress.
Researchers can employ this polyclonal knockout population in RhoA GTPase activation assays, western blotting for phospho-MLC, and immunofluorescence staining of filamentous actin to assess cytoskeletal changes. Functional assays include wound-healing migration and transwell invasion studies, while transcriptomic approaches such as RNA-seq reveal ARHGEF12-dependent gene expression networks. Co-immunoprecipitation and cell adhesion assays further elucidate protein interactions and adhesive properties. For additional information, please contact Ascent Research.
